These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 23911289)

  • 1. A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters.
    Hatzi K; Jiang Y; Huang C; Garrett-Bakelman F; Gearhart MD; Giannopoulou EG; Zumbo P; Kirouac K; Bhaskara S; Polo JM; Kormaksson M; MacKerell AD; Xue F; Mason CE; Hiebert SW; Prive GG; Cerchietti L; Bardwell VJ; Elemento O; Melnick A
    Cell Rep; 2013 Aug; 4(3):578-88. PubMed ID: 23911289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.
    Parekh S; Polo JM; Shaknovich R; Juszczynski P; Lev P; Ranuncolo SM; Yin Y; Klein U; Cattoretti G; Dalla Favera R; Shipp MA; Melnick A
    Blood; 2007 Sep; 110(6):2067-74. PubMed ID: 17545502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.
    Polo JM; Dell'Oso T; Ranuncolo SM; Cerchietti L; Beck D; Da Silva GF; Prive GG; Licht JD; Melnick A
    Nat Med; 2004 Dec; 10(12):1329-35. PubMed ID: 15531890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt.
    Juszczynski P; Chen L; O'Donnell E; Polo JM; Ranuncolo SM; Dalla-Favera R; Melnick A; Shipp MA
    Blood; 2009 Dec; 114(26):5315-21. PubMed ID: 19855081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.
    Ci W; Polo JM; Cerchietti L; Shaknovich R; Wang L; Yang SN; Ye K; Farinha P; Horsman DE; Gascoyne RD; Elemento O; Melnick A
    Blood; 2009 May; 113(22):5536-48. PubMed ID: 19307668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma.
    Saito M; Novak U; Piovan E; Basso K; Sumazin P; Schneider C; Crespo M; Shen Q; Bhagat G; Califano A; Chadburn A; Pasqualucci L; Dalla-Favera R
    Proc Natl Acad Sci U S A; 2009 Jul; 106(27):11294-9. PubMed ID: 19549844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas.
    Jiang Y; Ortega-Molina A; Geng H; Ying HY; Hatzi K; Parsa S; McNally D; Wang L; Doane AS; Agirre X; Teater M; Meydan C; Li Z; Poloway D; Wang S; Ennishi D; Scott DW; Stengel KR; Kranz JE; Holson E; Sharma S; Young JW; Chu CS; Roeder RG; Shaknovich R; Hiebert SW; Gascoyne RD; Tam W; Elemento O; Wendel HG; Melnick AM
    Cancer Discov; 2017 Jan; 7(1):38-53. PubMed ID: 27733359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCL6 represses CHEK1 and suppresses DNA damage pathways in normal and malignant B-cells.
    Ranuncolo SM; Polo JM; Melnick A
    Blood Cells Mol Dis; 2008; 41(1):95-9. PubMed ID: 18346918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of action of BCL6 during germinal center B cell development.
    Huang C; Melnick A
    Sci China Life Sci; 2015 Dec; 58(12):1226-32. PubMed ID: 26566802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.
    Cerchietti LC; Hatzi K; Caldas-Lopes E; Yang SN; Figueroa ME; Morin RD; Hirst M; Mendez L; Shaknovich R; Cole PA; Bhalla K; Gascoyne RD; Marra M; Chiosis G; Melnick A
    J Clin Invest; 2010 Dec; 120(12):4569-82. PubMed ID: 21041953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo.
    Cerchietti LC; Yang SN; Shaknovich R; Hatzi K; Polo JM; Chadburn A; Dowdy SF; Melnick A
    Blood; 2009 Apr; 113(15):3397-405. PubMed ID: 18927431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AID assists DNMT1 to attenuate BCL6 expression through DNA methylation in diffuse large B-cell lymphoma cell lines.
    Jiao J; Lv Z; Zhang P; Wang Y; Yuan M; Yu X; Otieno Odhiambo W; Zheng M; Zhang H; Ma Y; Ji Y
    Neoplasia; 2020 Mar; 22(3):142-153. PubMed ID: 32062068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas.
    Polo JM; Juszczynski P; Monti S; Cerchietti L; Ye K; Greally JM; Shipp M; Melnick A
    Proc Natl Acad Sci U S A; 2007 Feb; 104(9):3207-12. PubMed ID: 17360630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein.
    Dhordain P; Albagli O; Lin RJ; Ansieau S; Quief S; Leutz A; Kerckaert JP; Evans RM; Leprince D
    Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10762-7. PubMed ID: 9380707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma.
    Pasqualucci L; Migliazza A; Basso K; Houldsworth J; Chaganti RS; Dalla-Favera R
    Blood; 2003 Apr; 101(8):2914-23. PubMed ID: 12515714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis.
    Hatzi K; Melnick A
    Trends Mol Med; 2014 Jun; 20(6):343-52. PubMed ID: 24698494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells.
    Basso K; Saito M; Sumazin P; Margolin AA; Wang K; Lim WK; Kitagawa Y; Schneider C; Alvarez MJ; Califano A; Dalla-Favera R
    Blood; 2010 Feb; 115(5):975-84. PubMed ID: 19965633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas.
    Duan S; Cermak L; Pagan JK; Rossi M; Martinengo C; di Celle PF; Chapuy B; Shipp M; Chiarle R; Pagano M
    Nature; 2012 Jan; 481(7379):90-3. PubMed ID: 22113614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis.
    Béguelin W; Teater M; Gearhart MD; Calvo Fernández MT; Goldstein RL; Cárdenas MG; Hatzi K; Rosen M; Shen H; Corcoran CM; Hamline MY; Gascoyne RD; Levine RL; Abdel-Wahab O; Licht JD; Shaknovich R; Elemento O; Bardwell VJ; Melnick AM
    Cancer Cell; 2016 Aug; 30(2):197-213. PubMed ID: 27505670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acetylation inactivates the transcriptional repressor BCL6.
    Bereshchenko OR; Gu W; Dalla-Favera R
    Nat Genet; 2002 Dec; 32(4):606-13. PubMed ID: 12402037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.